Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy. Spero’s stock price was up 245.89% at last check Wednesday following the news. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned interim analysis of data from 1,690 patients enrolled in the study. Also Read: GSK To Buy Phase-3 Ready Liver Di ...